Premium Industrial News

Big Pharma Reacts to Russia's Move on Ukraine

Big Pharma Reacts to Russia's Move on Ukraine

pharmaceutical

Industry Segment: Pharmaceutical & Biotech | Word Count: 244 Words
Attachment: Map

May 25, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--While promising to keep the availability of essential drugs needed by Russian citizens, major drug companies have responded to the Ukraine invasion from a financial position. The responses all seem to center on cancelling or halting planned capital investments, along with discontinuation of clinical trials in Russia. Nobody currently in a clinical trial will be abandoned, but no new studies will be started.

Companies featured: Pfizer Incorporated, (NYSE:PFE) (New York, New York), Novartis International AG (NYSE:NVS), Novo Nordisk A/S (NYSE:NVO), Eli Lilly (NYSE:LLY)

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now!(All Fields Required)

Subscription Type:

  • Pay-Per-Article - $5.95
  • Annual Premium News Subscription - $365.00
Pricing Help?